Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Regulus Therapeutics Inc. | rgls20160630-10q.htm |
| EX-31.2 - EXHIBIT 31.2 - Regulus Therapeutics Inc. | ex-312x20160630.htm |
| EX-31.1 - EXHIBIT 31.1 - Regulus Therapeutics Inc. | ex-31120160630.htm |
| EX-10.1 - EXHIBIT 10.1 - Regulus Therapeutics Inc. | ex-10120160630.htm |
| EX-3.1 - EXHIBIT 3.1 - Regulus Therapeutics Inc. | ex-3120160630.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Regulus Therapeutics Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul C. Grint, M.D., President and Chief Executive Officer and I, Joseph P. Hagan, Chief Operating Officer and Principal Financial and Accounting Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 2, 2016 | /s/ Paul C. Grint | |
Paul C. Grint, M.D. | ||
President and Chief Executive Officer | ||
(Principal Executive Officer) | ||
Date: August 2, 2016 | /s/ Joseph P. Hagan | |
Joseph P. Hagan | ||
Chief Operating Officer | ||
(Principal Financial and Accounting Officer) | ||
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.